<DOC>
	<DOCNO>NCT02361138</DOCNO>
	<brief_summary>SHR3824 novel inhibitor renal sodium-glucose cotransporter 2 , allow insulin-independent approach improve type 2 diabetes hyperglycemia . In multiple-dose study investigator evaluate safety , tolerability PK/PD profile SHR3824 healthy subject .</brief_summary>
	<brief_title>The PK/PD Study Multiple Dose SHR3824 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Chinese male female subject age 18 45 year . BMI:18 25 kg/m2 . Healthy accord medical history , physical examination finding , 12lead ECG finding , clinical laboratory evaluation . Exclusion criterion : History current clinically significant medical illness determine Investigator . History clinically significant allergy , especially know hypersensitivity intolerance lactose . Pregnancy breastfeed . Significant acute chronic medical illness , include renal impairment , recent surgery . Donation blood plasma within 4 week prior start study acceptance blood transfusion within 8 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>SHR3824 Type 2 diabetes mellitus SGLT2</keyword>
</DOC>